Royalty Report: Diagnostic, Drugs, Disease – Collection: 6572

License Grant

Pursuant to an agreement dated February 9, 2009 between the Company, and the Licensor, a California Corporation, the Licensee, is obligated to make payments, from earnings generated from Research derived from the biological specimens from Parkinson's disease patients and control patients provided by the Licensor.

License Property

IP relates to biomarkers for Parkinson's disease.

Field of Use

The Field of Use apply to the healthcare industry.  Licensee has an ongoing collaboration with the Parkinson’s Institute to test known Parkinson’s Disease (PD) patients’ blood to identify biomarkers for Parkinson’s Disease from the human plasma proteome microarray marketed as PlasmaScanâ„¢.  Licensee is also using the H25K Whole Human Genome Microarray to examine PD samples and has identified the world’s first functional mRNA biomarkers for Parkinson’s Disease. An expanded patient study will be used to further validate the PD biomarkers.  Licensee is also working with Stanford University to test known Alzheimer’s patients’ blood to identify biomarkers for Alzheimer’s Disease using PlasmaScan and other tools.

License Grant

The Licensor and the Licensee entered into a License Agreement whereby the Licensee is obligated to make payments on earnings generated from Research derived from the biological specimens provided by the Licensor.

License Property

The Licensor will provide the biological specimens from Parkinson's disease patients and control patients.

Field of Use

The Licensee has a line of products and services serving the sequencing, genotyping, gene expression and protein analysis markets.

License Grant

A licensor granted an exclusive non-transferable world-wide license to certain patents it owns. The technology is to be used to commercialize biomarkers for detection of Alzheimer’s Disease (AD).  The licensee is a newly formed bio-science company.  The licensor owns through an affiliate at least 20% of licensee.

License Property

Licensed Technology. The term Licensed Technology shall mean all trade secrets, know-how, and other confidential and proprietary information owned by Licensor or licensed to Licensor by Licensor on or subsequent to the Effective Date, to the extent covering any of the following

(i) in vitro therapeutic test system that uses cultured human fibroblasts or any other method to detect and measure PKC and/or other assays with peripheral cells to predict the presence of Alzheimer’s Disease in humans, and all succeeding test formats (including test kits);

(ii) the PKC activators (including bryostatin, analogs, PUFAs, and other PKC activators) and their therapeutic applications in humans or animals;

(iii) the LDL or ApoE-based drug delivery system that is targeted to enhance access of all manner of drugs and therapeutics to the brain by facilitation of transport of such drugs across the Blood-Brain-Barrier in humans or animals; and

(iv) the carbonic anhydrase activators and their therapeutic applications in humans or animals

Effective August 28, 2013, licensee signed a statement of work (SOW) with licensor pursuant to the License Agreement, whereby the Company has contracted for the further development of its AD diagnostic product. The project is intended to validate each of three biomarkers in a heterogeneous patient population to determine sensitivity and selectivity parameters for each biomarker, or combination of biomarkers, to detect Alzheimer’s Disease. The three biomarkers to be evaluated are the PKCe levels, the Erk1/2 ratios, and the fibroblast morphology test.

Field of Use

The term Field of Use shall mean the field of use of the Licensed IP in humans or animals for therapeutic or diagnostic applications for Alzheimer’s Disease or other cognitive dysfunctions.

License Grant

College hereby grants to Licensee an exclusive, worldwide, sublicensable license under the Patent Rights to make, have made, use, market, sell, offer to sell, lease and import Licensed Products in the Field.

License Property

Technologies are biomarkers that directly impact the diagnosis of neurodegenerative diseases.   Licensee , in collaboration with College, have applied the latest proteomic techniques to the differential diagnosis of neurodegenerative diseases utilizing blood serum.

The term Patent Rights shall mean United States Patent Application Serial No. TBA, entitled 'Biomarkers for Neurodegenerative Disease,' filed TBA, which was developed by the Inventors, the inventions described and claimed therein, and all other pending United States patent applications or parts thereof and any United States patent which issues from any such pending applications and any and all divisions, reissues, re-examinations, renewals, continuations, continuations-in-part to the extent the claims are directed to subject matter specifically described in the aforementioned patent application and are dominated by the claims of the existing Patent Rights, and extensions thereof, and all other counterpart, pending or issued patents in all other countries.

Re College OTA # 04-107 Entitled 'Serum Proteomic Methods and Biomarkers for Diagnosis of Neurodegenerative Disease and Differential Diagnosis of Alzheimers, Parkinsons Lou Gehrigs (ALS) Diseases, and other Motor Neuron and Neurological Disorders'

The term Licensed Product(s) shall mean any product, process or service that incorporates, utilizes or is made with the use of the Patent Rights.

Field of Use

This agreement pertains to the drug industry relating to Diagnosis of Neurodegenerative Disease and Differential Diagnosis of Alzheimers, Parkinsons Lou Gehrigs (ALS) Diseases, and other Motor Neuron and Neurological Disorders in the Field that shall mean all fields.

License Grant

The Company of the United Kingdom obtained a worldwide, royalty-bearing, exclusive license under any patents and any related know-how Licensor, a diabetes research center,  related to the patent application filed with respect to the use the TNFR1 and TNFR2 biomarkers (Licensor IP).  This includes to make, have made, use, offer for sale and sell licensed products covered by claims in the Licensor IP, and to perform, practice offer for sale and sell certain licensed processes related to the Licensor IP.

License Property

Licensor IP means the Tumor Necrosis Factor (TNFR1 and TNFR2) biomarkers that are in the multiplex assay plate used for determining whether a patient has an increased risk of developing chronic kidney disease (CKD) or end-stage kidney disease (ESKD). Blood-based biomarkers are typically genes or proteins that indicate the existence and severity of certain conditions (such as kidney disease) and can be measured from a simple blood sample.

Licensor is an institution devoted to diabetes research, care, and education.

Field of Use

The biomarkers are used to determine the patients risk of developing kidney disease.  Biomarkers can be measured through a blood sample.

The Licensee is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease.

License Grant

University granted the Licensee an exclusive, worldwide, sublicensable license in all fields under University’s Codex patent estate under certain patent rights to make, use, import and commercialize products for diagnostic, industrial and research and development purposes.

License Property

Patents shall mean the ones under Universitys Codex patent estate.

CODEX, is an ultra-high parameter and cost-effective platform ideally suited for discovery research with the ability to identify more than 40 biomarkers in a tissue sample.

Field of Use

Field of use is in all fields to identify biomarkers for diagnostic, industrial and research and development purposes.

Biomarkers are objective measures that capture what is happening in a cell or tissue at a given moment. Current genomic and proteomic methods, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry, are providing meaningful data but require the destruction of the tissue sample for analysis.